ARDELYX Files 8-K on Operations & Financial Condition

TL;DR

**ARDELYX just dropped an 8-K on its financials, time to check their numbers.**

AI Summary

ARDELYX, INC. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition. This filing updates investors on the company's current financial status and operational performance, which is crucial for shareholders to understand the health and trajectory of the company. For investors, this matters because it provides timely insight into ARDELYX's financial stability and growth prospects, directly influencing their investment decisions.

Why It Matters

This filing provides a current snapshot of ARDELYX's financial health, allowing investors to assess its performance and make informed decisions about buying, holding, or selling the stock.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial condition and operations, not indicating any immediate new risks.

Analyst Insight

Investors should review the detailed financial statements and results of operations that will be included in this 8-K to understand the company's current performance and future outlook.

Key Numbers

• January 8, 2024 — Date of Report (The earliest event reported in this 8-K filing.)
• $0.0001 — par value (The par value per share of ARDELYX, INC. Common Stock.)

Key Players & Entities

• ARDELYX, INC. (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for ARDELYX, INC.
• 001-36485 (dollar_amount) — Commission File Number for ARDELYX, INC.
• 26-1303944 (dollar_amount) — IRS Employer Identification Number for ARDELYX, INC.
• ARDX (company) — trading symbol for ARDELYX, INC. Common Stock
• The Nasdaq Global Market (company) — exchange where ARDELYX, INC. Common Stock is registered

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 ARDX The Nasdaq Global Market Indicat
• $28 million — of IBSRELA (tenapanor) of approximately $28 million for the fourth quarter ended December 3
• $80 million — ed December 31, 2023, and approximately $80 million for the full year ended December 31, 20
• $2.5 million — of XPHOZAH (tenapanor) of approximately $2.5 million for the fourth quarter ended December 3
• $184 m — short-term investments of approximately $184 million, unaudited. These amounts are pre

Filing Documents

• ardx-20240108.htm (8-K) — 26KB
• ardx-20240108_g1.jpg (GRAPHIC) — 3KB
• 0001628280-24-000772.txt ( ) — 159KB
• ardx-20240108.xsd (EX-101.SCH) — 2KB
• ardx-20240108_lab.xml (EX-101.LAB) — 24KB
• ardx-20240108_pre.xml (EX-101.PRE) — 13KB
• ardx-20240108_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 8, 2024, Ardelyx, Inc. (the "Company") announced unaudited U.S. net product sales revenue of IBSRELA (tenapanor) of approximately $28 million for the fourth quarter ended December 31, 2023, and approximately $80 million for the full year ended December 31, 2023. The Company announced unaudited U.S. net product sales revenue of XPHOZAH (tenapanor) of approximately $2.5 million for the fourth quarter ended December 31, 2023. The Company also announced that as of December 31, 2023, it had cash, cash equivalents, and short-term investments of approximately $184 million, unaudited. These amounts are preliminary and are subject to adjustment in connection with preparation of audited financial statements. As a result, these amounts may differ materially from the amounts that will be reflected in the Company's financial statements for the year ended December 31, 2023. The preliminary financial data included in this Current Report on Form 8-K has been prepared by, and is the responsibility of, the Company's management. Ernst & Young LLP has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, Ernst & Young LLP does not express an opinion or any other form of assurance with respect thereto. The information in Item 2.02 of this Current Report on Form 8-K is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 ARDELYX, INC. By: /s/ Justin Renz Justin Renz Chief Financial and Operations Officer

View Full Filing

View this 8-K filing on SEC EDGAR